|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's range||96.07 - 100.62|
|52-week range||80.95 - 106.66|
|Beta (5Y monthly)||0.36|
|PE ratio (TTM)||18.94|
|Earnings date||28 Jul 2022|
|Forward dividend & yield||3.33 (3.31%)|
|Ex-dividend date||06 May 2022|
|1y target est||111.66|
Mega-blockbuster Dupixent was just given the FDA's green light to treat patients with a chronic, progressive inflammatory disease.
Global biopharmaceutical company Sanofi (NASDAQ: SNY) encountered setbacks while developing its COVID-19 vaccine, and only this year reported results from late-stage clinical trials. Sanofi opted for the more traditional protein-based technology for its COVID-19 vaccine, Vidprevtyn, rather than the mRNA technology of Pfizer-BioNTech's Comirnaty and Moderna's Spikevax. The mRNA technology delivers genetic code instructing the body's cells to make the protein, while the more traditional approach produces the protein in a lab before injecting it into the body.
Availability of the Q2 2022 Memorandum for modelling purposes Paris, France – June 24, 2022 - Sanofi announced today that its Q2 2022 Memorandum for modelling purposes is available on the "Investors" page of the company's website: https://www.sanofi.com/en/investors/financial-results-and-events/financial-results/Q2-results-2022 As for each quarter, Sanofi prepared this document to assist in the financial modelling of the Group's quarterly results. This document includes a reminder on various non